Abstract: Provided is a dual recombinant viral vector system for expressing, in a cell, a polypeptide molecule which is composed of two different peptide chains and has an antigen binding activity, wherein the first chain is expressed using a first viral vector, the second chain is expressed using a second viral vector, and the first and second chains can be assembled, after being expressed in a cell, into the polypeptide molecule which has an antigen binding activity. Further provided are a dual plasmid system for the production of the dual recombinant viral vector system, a host cell containing the dual recombinant viral vector system, a pharmaceutical composition, and the use of and the method for delivering the polypeptide molecule to a subject by using the dual recombinant viral vector system.

Abstract: The present invention relates to a humanized anti-human OX40 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human OX40 monoclonal antibody provided in the present invention has high affinity and specificity for OX40, and can stimulate T cells to secrete cytokines, for example, specifically activate the positive immune regulation by OX40 and activate T cells to secrete cytokines. Therefore, the functional humanized anti-human OX40 monoclonal antibody provided in the present invention activates T cells by activating the OX40 signaling pathway, thereby achieving the purpose of tumor immunotherapy.

Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.